atagabalin

Uses your system voice; voice and rate in settings.

Q4812635Snapshot

≈ 1 min read

Names in other languages

  • Englishatagabalin
  • igAtagabalin
  • shAtagabalin
  • СрпскиAtagabalin
  • 中文PD-200,390
  • 日本語アタガバリン

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Atagabalin ( , ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.

Atagabalin ( , ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.

See also

List of investigational insomnia drugs 4-Methylpregabalin Gabapentin enacarbil PD-217,014 PD-0299685

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083041 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.